ATE268178T1 - Stabile medizinische zusammenstellungen die 4,5- epoxymorphinanderivate enthalten - Google Patents

Stabile medizinische zusammenstellungen die 4,5- epoxymorphinanderivate enthalten

Info

Publication number
ATE268178T1
ATE268178T1 AT98931040T AT98931040T ATE268178T1 AT E268178 T1 ATE268178 T1 AT E268178T1 AT 98931040 T AT98931040 T AT 98931040T AT 98931040 T AT98931040 T AT 98931040T AT E268178 T1 ATE268178 T1 AT E268178T1
Authority
AT
Austria
Prior art keywords
derivatives
epoxymorphine
compositions containing
medical compositions
stable medical
Prior art date
Application number
AT98931040T
Other languages
English (en)
Inventor
Nobuyuki Hanamura
Yasuhide Horiuchi
Ryoji Yoshii
Takao Aoki
Michio Hara
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Application granted granted Critical
Publication of ATE268178T1 publication Critical patent/ATE268178T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Materials For Medical Uses (AREA)
AT98931040T 1997-07-11 1998-07-10 Stabile medizinische zusammenstellungen die 4,5- epoxymorphinanderivate enthalten ATE268178T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP18695097 1997-07-11
PCT/JP1998/003096 WO1999002158A1 (fr) 1997-07-11 1998-07-10 Compositions medicinales stables, contenant des derives de 4,5-epoxymorphinane

Publications (1)

Publication Number Publication Date
ATE268178T1 true ATE268178T1 (de) 2004-06-15

Family

ID=16197570

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98931040T ATE268178T1 (de) 1997-07-11 1998-07-10 Stabile medizinische zusammenstellungen die 4,5- epoxymorphinanderivate enthalten

Country Status (15)

Country Link
US (1) US6372755B2 (de)
EP (1) EP0948965B1 (de)
JP (3) JP3617055B2 (de)
KR (1) KR100514963B1 (de)
CN (1) CN100379419C (de)
AT (1) ATE268178T1 (de)
AU (1) AU740404B2 (de)
CA (1) CA2265767C (de)
DE (1) DE69824277T2 (de)
DK (1) DK0948965T3 (de)
ES (1) ES2217563T3 (de)
NO (1) NO318831B1 (de)
PT (1) PT948965E (de)
TW (1) TWI285644B (de)
WO (1) WO1999002158A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899400A0 (en) * 2000-07-26 2000-08-17 Csl Limited A method of stabilisation and compositions for use therein
SG90259A1 (en) * 2000-08-17 2002-07-23 Control Ox Oy Plant-derived and synthetic phenolic compounds and plant extracts, effective in the treatment and prevention of chlamydial infections
JP4880813B2 (ja) * 2000-10-26 2012-02-22 第一三共株式会社 外用消炎鎮痛剤組成物
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
DE10161149B4 (de) * 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum
DE10161110A1 (de) * 2001-12-12 2003-06-26 Ursapharm Arzneimittel Gmbh Pharmazeutische Zusammensetzung zur ophthalmologischen und rhinologischen Anwendung
ZA200409537B (en) * 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
GB0308734D0 (en) * 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
JP4963670B2 (ja) * 2004-04-07 2012-06-27 レスベラトロル パートナーズ, エルエルシー 栄養補助サプリメントおよびそれを処理する方法
US8288362B2 (en) 2004-05-07 2012-10-16 S.K. Pharmaceuticals, Inc. Stabilized glycosaminoglycan preparations and related methods
WO2005110439A2 (en) * 2004-05-07 2005-11-24 S.K. Pharmaceuticals, Inc. Stabilized hyaluronan preparations and related methods
WO2006024138A1 (en) * 2004-08-30 2006-03-09 Taro Pharmaceutical Industries Ltd. A thermoreversible pharmaceutical formulation for anti-microbial agents comprising poloxamer polymers and hydroxy fatty acid ester of polyethylene glycol
WO2006067605A1 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Stable pharmaceutical compositions of tiagabine and processes for their preparation
CN101150956B (zh) * 2005-01-27 2013-04-17 埃里莫斯医药品有限公司 用于注射入动物的包括ndga化合物的儿茶酚丁烷配方
US20080096967A1 (en) * 2005-01-27 2008-04-24 Erimos Pharmaceuticals Llc Formulations for Injection of Catecholic Butanes, Including Ndga Compounds, Into Animals
TWI286941B (en) * 2005-07-27 2007-09-21 Anagen Therapeutics Inc Stabilized pharmaceutical and cosmetic composition of catechins or derivatives thereof
PL2151241T3 (pl) * 2007-04-26 2012-08-31 Toray Industries Trwały stały preparat zawierający pochodną 4,5-epoksymorfinanową
ES2648037T3 (es) * 2007-05-21 2017-12-28 Toray Industries, Inc. Preparación oral que comprende un ácido orgánico específico y método para mejorar la propiedad de disolución y la estabilidad química de la preparación oral
CN101658489B (zh) * 2008-08-27 2011-11-23 海南四环心脑血管药物研究院有限公司 一种盐酸纳美芬注射液及其制备方法
BRPI0920599B1 (pt) * 2008-10-24 2021-10-19 Toray Industries, Inc. Comprimido estável contendo um derivado de 4,5-epoximorfinano
TWI455733B (zh) 2009-03-30 2014-10-11 Toray Industries 口腔內崩壞性被覆錠劑
AU2010255747B2 (en) * 2009-06-04 2014-03-13 Alk-Abello A/S Stabilised composition comprising at least one adrenergic compound
ES2933198T3 (es) 2010-10-21 2023-02-02 Rtu Pharmaceuticals Llc Formulaciones de ketorolaco listas para usar
JP5750278B2 (ja) * 2011-02-28 2015-07-15 東洋カプセル株式会社 カンデサルタンシレキセチルのカプセル充填用組成物
WO2013070656A1 (en) * 2011-11-07 2013-05-16 Navinta Llc Sustained release suspension preparation for dextromethorphan
WO2013074948A1 (en) 2011-11-16 2013-05-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
JP6064252B2 (ja) * 2012-01-19 2017-01-25 三笠製薬株式会社 そう痒症改善経皮吸収貼付剤
JP6247118B2 (ja) * 2014-03-05 2017-12-13 東海カプセル株式会社 カプセル充填組成物
CA2980097C (en) 2015-03-19 2019-10-29 Daiichi Sankyo Company, Limited Solid preparation containing colorant
EP3272345B1 (de) * 2015-03-19 2019-10-16 Daiichi Sankyo Company, Limited Feststoffpräparat mit antioxidationsmittel
JP5918894B1 (ja) * 2015-05-21 2016-05-18 富士カプセル株式会社 ナルフラフィン塩酸塩含有カプセル製剤
TW201707703A (zh) * 2015-06-04 2017-03-01 Tokai Capsule Co Ltd 軟膠囊劑
CN119157840A (zh) 2016-07-29 2024-12-20 东丽株式会社 光稳定性提高的固体制剂
JP6131379B1 (ja) * 2016-12-28 2017-05-17 森下仁丹株式会社 4,5−エポキシモルヒナン誘導体含有製剤
JP7153197B2 (ja) * 2017-03-31 2022-10-14 東レ株式会社 ナルフラフィンを含有する錠剤化された医薬組成物
AU2019229892B2 (en) 2018-03-08 2025-01-30 University Of Kansas Treatment of demyelinating diseases
KR102849723B1 (ko) 2018-07-30 2025-08-22 다이이찌 산쿄 가부시키가이샤 안정화제를 함유하는 의약품의 고형 제제
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device
WO2020205735A1 (en) 2019-03-29 2020-10-08 Humanwell Pharmaceutical US Novel morphinans useful for treating medical disorders
EP4062973A4 (de) * 2019-11-20 2023-11-29 Shionogi & Co., Ltd 6,7-ungesättigtes-7-carbamoyl-morphinanderivat enthaltende feste formulierung
PE20250155A1 (es) 2021-06-14 2025-01-22 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2765694B2 (ja) * 1988-01-29 1998-06-18 日清バーディシェ株式会社 酸化感受性化合物の安定な組成物
GB8820327D0 (en) 1988-08-26 1988-09-28 May & Baker Ltd New compositions of matter
ES2121988T3 (es) * 1992-01-23 1998-12-16 Toray Industries Derivado de morfinano y uso medicinal.
NZ268969A (en) * 1993-07-23 1997-06-24 Toray Industries Morphinan derivatives and pharmaceutical compositions
US5948389A (en) * 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
DE29719704U1 (de) 1997-02-14 1998-01-22 Gödecke AG, 10587 Berlin Stabile Zubereitungen von Naloxonhydrochlorid

Also Published As

Publication number Publication date
JP3617055B2 (ja) 2005-02-02
CN100379419C (zh) 2008-04-09
DE69824277D1 (de) 2004-07-08
ES2217563T3 (es) 2004-11-01
JP3743449B2 (ja) 2006-02-08
CN1237106A (zh) 1999-12-01
NO318831B1 (no) 2005-05-09
AU740404B2 (en) 2001-11-01
KR100514963B1 (ko) 2005-09-15
CA2265767C (en) 2007-12-04
DK0948965T3 (da) 2004-07-05
US20010004637A1 (en) 2001-06-21
CA2265767A1 (en) 1999-01-21
EP0948965B1 (de) 2004-06-02
JP2005247866A (ja) 2005-09-15
PT948965E (pt) 2004-08-31
NO991152D0 (no) 1999-03-10
DE69824277T2 (de) 2004-09-23
US6372755B2 (en) 2002-04-16
EP0948965A4 (de) 2002-10-16
KR20000068528A (ko) 2000-11-25
NO991152L (no) 1999-05-10
JP2005002123A (ja) 2005-01-06
TWI285644B (en) 2007-08-21
AU8128298A (en) 1999-02-08
WO1999002158A1 (fr) 1999-01-21
EP0948965A1 (de) 1999-10-13
JP4311369B2 (ja) 2009-08-12

Similar Documents

Publication Publication Date Title
DE69824277D1 (de) Stabile medizinische zusammenstellungen die 4,5-epoxymorphinanderivate enthalten
ES2201644T3 (es) Composicion farmaceutica a base de estrogeno y de progesterona.
PT698393E (pt) Agente de solubilizacao e preparacao para uso externo contendo o mesmo
CY1105112T1 (el) Διαμορφωσεις δια καταπολεμησιν ανθρωπινων φθειρων, πepιεχουσαι σπινοσυνη (spinosyn)
ATE225341T1 (de) In 6-position durch thio substituierte paclitaxele
DE60104206D1 (de) Halbfeste arzneizubereitung enthaltend isotretinoin
DK0588539T3 (da) Stabiliserede farmaceutiske præparater indeholdende derivater af vitamin D2 og D3
DE59400489D1 (de) Fungizide Wirkstoffkombinationen
ES2150989T3 (es) Nuevos derivados de quinoxalinadiona, su preparacion y empleo en medicamentos.
ES2118955T3 (es) Derivados de dolastatina.
ES2190082T3 (es) Concentrados estables de vitamina c.
DE69818516D1 (de) Phenylaminoalkylcarbonsäure-derivate und medizinische zusammensetzungen, die diese enthalten
DE69019035D1 (de) Stabilisierte fettlösliche Vitaminzusammensetzungen.
DE69227745D1 (de) Pharmazeutische Zusammensetzungen zur topischen Anwendung die ein Chelatierungsmittel, ein Tocopherol und einen antimikrobiellen Wirkstoff enthalten
DZ1926A1 (fr) Formulations pharmaceutiques.
EP1084710A4 (de) Medikamente gegen männliche sterilität
ATE181324T1 (de) Im kardiovaskulären system aktive seco-d-steroide und diese enthaltende pharmazeutische zubereitungen
NZ223521A (en) Substituted n-phenyl benzamide derivatives and anticonvulsive pharmaceutical compositions
NO923266L (no) Heksahydrobenzo(f)quinolinoner
MX9203616A (es) Derivados de 4-amidino cromano y de 4-amidino[3,2-c] piridina y composiciones farmaceuticas que los contienen.
DE69114922D1 (de) Polysulfidverbindungen und Lipidperoxidierungsinhibitore, die diese Polysulfidverbindungen als aktive Zutaten enthalten.
AR008474A1 (es) Derivado de 9-dihidroeritromicina a 6,9; 11,12-diciclocarbonato, composicion farmaceutica y preparacion bactericida que lo contienen y su uso
BG104692A (en) Extended release tiagabine formulation
ATE230602T1 (de) Zubereitung, enthaltend vx 478 und eine wasserlösliche vitamin e verbindung wie vitamin e-tpgs
FR2718444B1 (fr) Dérivés de (3-méthyl-1, 2, 3, 4-tétrahydroquinoléin-8-yl)sulfonyle, leur préparation et leur application en thérapeutique.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0948965

Country of ref document: EP